임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

27건 표시

3상모집 중· Colorectal Cancer
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
리드: 애브비
상세 →NCT07525206
3상모집 중· Neovascular Age-related Macular Degeneration
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
리드: 애브비
상세 →NCT07007065
3상모집 중· Acne Scars
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
리드: 애브비
상세 →NCT07207369
3상모집 중· Ulcerative Colitis
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
리드: 애브비
상세 →NCT07071519
3상모집 중· Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
리드: 애브비
상세 →NCT07023302
3상모집 중· Colitis, Ulcerative
Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis
협력: 애브비
상세 →NCT06660693
3상모집 중· Chronic Migraine
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
리드: 애브비
상세 →NCT06810505
3상모집 중· Primary Open Angle Glaucoma
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
리드: 애브비
상세 →NCT06822738
3상모집 중· Mid Face Volume Deficit
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
리드: 애브비
상세 →NCT06734351
3상모집 중· Breast Reconstruction
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
리드: 애브비
상세 →NCT06575192
3상모집 중· Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
리드: 애브비
상세 →NCT06461897
3상모집 중· Crohn's Disease
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
리드: 애브비
상세 →NCT06332534
3상모집 중· Chronic Lymphocytic Leukemia
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
리드: 애브비
상세 →NCT06428019
3상모집 중· Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
리드: 애브비
상세 →NCT06100744
3상모집 중· Atopic Dermatitis
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
리드: 애브비
상세 →NCT06389136
3상모집 중· Multiple Myeloma
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
리드: 애브비
상세 →NCT06158841
3상모집 중· Follicular Lymphoma (FL)
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
협력: 애브비
상세 →NCT06191744
3상모집 중· Crohn's Disease
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
리드: 애브비
상세 →NCT05995353
3상모집 중· Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
리드: 애브비
상세 →NCT06012240
3상모집 중· Juvenile Idiopathic Arthritis
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
리드: 애브비
상세 →NCT05609630
3상모집 중· Hidradenitis Suppurativa
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
리드: 애브비
상세 →NCT05889182
3상모집 중· Episodic Migraine
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
리드: 애브비
상세 →NCT05711394
3상모집 중· Acute Myeloid Leukemia
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
협력: 애브비, 로슈
상세 →NCT05183035
3상모집 중· Non Small Cell Lung Cancer
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
리드: 애브비
상세 →NCT04928846
3상모집 중· AMD
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
리드: 애브비
상세 →NCT05407636
3상모집 중· Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
리드: 애브비
상세 →NCT05125302
3상모집 중· Depression
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
리드: 애브비
상세 →NCT04777357

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.